WO1993020839A3 - Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality - Google Patents
Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality Download PDFInfo
- Publication number
- WO1993020839A3 WO1993020839A3 PCT/US1993/003318 US9303318W WO9320839A3 WO 1993020839 A3 WO1993020839 A3 WO 1993020839A3 US 9303318 W US9303318 W US 9303318W WO 9320839 A3 WO9320839 A3 WO 9320839A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- renin
- mobidity
- mortality
- inhibitor
- myocardial infarct
- Prior art date
Links
- 208000010125 myocardial infarction Diseases 0.000 title abstract 3
- 229940123073 Angiotensin antagonist Drugs 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000036454 renin-angiotensin system Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002117782A CA2117782C (en) | 1992-04-10 | 1993-04-09 | Use of renin-angiotensin antagonist for reducing post myocardial infarct morbidity and mortality |
DE69333362T DE69333362T3 (en) | 1992-04-10 | 1993-04-09 | USE OF ANGIOTENSINE ANTAGONISTS (AT1) TO REDUCE DISEASE AND DEATH RISK TO MYOCARDINE FARCT |
JP5518479A JPH07505884A (en) | 1992-04-10 | 1993-04-09 | Use of renin-angiotensin antagonists to reduce morbidity and mortality after myocardial infarction |
DK93912155T DK0641218T4 (en) | 1992-04-10 | 1993-04-09 | Use of angiotensin antagonist (AT1) to reduce postmyocardial infarction morbidity and mortality |
EP93912155A EP0641218B2 (en) | 1992-04-10 | 1993-04-09 | Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/866,827 | 1992-04-10 | ||
US07/866,827 US5977160A (en) | 1992-04-10 | 1992-04-10 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US07/981,196 US5972990A (en) | 1992-04-10 | 1992-11-25 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US07/981,196 | 1992-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993020839A2 WO1993020839A2 (en) | 1993-10-28 |
WO1993020839A3 true WO1993020839A3 (en) | 1994-02-17 |
Family
ID=27127973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/003318 WO1993020839A2 (en) | 1992-04-10 | 1993-04-09 | Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality |
Country Status (9)
Country | Link |
---|---|
US (2) | US5972990A (en) |
EP (2) | EP0641218B2 (en) |
JP (1) | JPH07505884A (en) |
AU (1) | AU4281093A (en) |
CA (1) | CA2117782C (en) |
DE (1) | DE69333362T3 (en) |
DK (1) | DK0641218T4 (en) |
ES (1) | ES2211867T5 (en) |
WO (1) | WO1993020839A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2238770T5 (en) * | 1997-10-17 | 2012-01-17 | Ark Therapeutics Limited | USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPOXIA OR DECREASE OF METABOLIC FUNCTION. |
CN101011390A (en) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | Use of angiotensin II receptor antagonists for treating acute myocardial infarction |
SE9903028D0 (en) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
ES2246894T3 (en) * | 1999-08-30 | 2006-03-01 | Sanofi-Aventis Deutschland Gmbh | RAMIPRIL FOR THE PREVENTION OF CARDIOVASCULAR EVENTS. |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6808927B2 (en) * | 2001-04-04 | 2004-10-26 | American Diagnostica, Inc. | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof |
US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US7107198B2 (en) * | 2001-11-02 | 2006-09-12 | Sun Microsystems, Inc. | Automatic generation of reduced-size circuit models including inductive interaction |
FI20020197A0 (en) * | 2002-02-01 | 2002-02-01 | Orion Corp | A combination treatment method for acute myocardial infarction |
EP2204455A1 (en) * | 2002-08-29 | 2010-07-07 | American Diagnostica, Inc. | Diagnostic assay for thrombin-activatable fibrinolysis inhibitor (TAFI) |
WO2014055392A2 (en) * | 2012-10-01 | 2014-04-10 | Decimmune Therapeutics, Inc. | Method of protecting cardiac function |
ITFI20140115A1 (en) * | 2014-05-19 | 2015-11-19 | Italmed Srl | COMPOSITION FOR DENTAL USE FOR THE SURGICAL TREATMENT OF PERIMPLANTITIS |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
AU2019287551A1 (en) | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006379A1 (en) * | 1985-04-19 | 1986-11-06 | The Upjohn Company | Dihalo-statine substituted renin inhibitors |
EP0320205A2 (en) * | 1987-12-07 | 1989-06-14 | Glaxo Group Limited | Renin inhibiting dipeptides, their preparation and compositions containing them |
EP0366033A2 (en) * | 1988-10-24 | 1990-05-02 | E.R. SQUIBB & SONS, INC. | Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination |
EP0434249A2 (en) * | 1989-12-01 | 1991-06-26 | Glaxo Group Limited | Benzofuran derivatives |
EP0499414A2 (en) * | 1991-02-11 | 1992-08-19 | Zeneca Limited | Pyridine derivatives as angiotensin II antagonists, processes for their preparation and pharmaceutical compositions containing them |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302386A (en) * | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US3932624A (en) * | 1974-06-17 | 1976-01-13 | Morton-Norwich Products, Inc. | Method for prolonging the inhibitory effect of saralasin on angiotensin II |
US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4508729A (en) * | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) * | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
US4780401A (en) * | 1984-04-09 | 1988-10-25 | Ciba-Geigy Corporation | Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications |
US4845079A (en) * | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) * | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) * | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) * | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4816463A (en) * | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US5063053A (en) * | 1986-10-20 | 1991-11-05 | The United States Of America As Represented By The Department Of Health & Human Services | Isolation and purification of the R18 antigen of HTLV-III |
US4772684A (en) * | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US4980283A (en) * | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5034512A (en) * | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) * | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) * | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5081127A (en) * | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US5036054A (en) * | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) * | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (en) * | 1988-12-09 | 1990-06-13 | Hoechst Ag | ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE |
US5106835A (en) * | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
DE4004820A1 (en) * | 1989-08-05 | 1991-04-25 | Bayer Ag | RENININHIBITORS, METHOD FOR THE PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US5063208A (en) * | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) * | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) * | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
US5098471A (en) * | 1989-12-06 | 1992-03-24 | Westinghouse Electric Corp. | Separation of magnesium from magnesium chloride and zirconium and/or hafnium subchlorides in the production of zirconium and/or hafnium sponge metal |
US5064965A (en) * | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) * | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) * | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5085992A (en) * | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5087634A (en) * | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US5071837A (en) * | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
SI9210098B (en) † | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoles, drugs with this compounds, and process for their preparation |
US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
-
1992
- 1992-11-25 US US07/981,196 patent/US5972990A/en not_active Expired - Lifetime
-
1993
- 1993-04-09 WO PCT/US1993/003318 patent/WO1993020839A2/en active IP Right Grant
- 1993-04-09 EP EP93912155A patent/EP0641218B2/en not_active Expired - Lifetime
- 1993-04-09 ES ES93912155T patent/ES2211867T5/en not_active Expired - Lifetime
- 1993-04-09 AU AU42810/93A patent/AU4281093A/en not_active Abandoned
- 1993-04-09 DK DK93912155T patent/DK0641218T4/en active
- 1993-04-09 CA CA002117782A patent/CA2117782C/en not_active Expired - Lifetime
- 1993-04-09 EP EP02019101A patent/EP1262175A3/en not_active Ceased
- 1993-04-09 DE DE69333362T patent/DE69333362T3/en not_active Expired - Lifetime
- 1993-04-09 JP JP5518479A patent/JPH07505884A/en active Pending
-
1995
- 1995-06-07 US US08/476,661 patent/US5952305A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006379A1 (en) * | 1985-04-19 | 1986-11-06 | The Upjohn Company | Dihalo-statine substituted renin inhibitors |
EP0320205A2 (en) * | 1987-12-07 | 1989-06-14 | Glaxo Group Limited | Renin inhibiting dipeptides, their preparation and compositions containing them |
EP0366033A2 (en) * | 1988-10-24 | 1990-05-02 | E.R. SQUIBB & SONS, INC. | Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination |
EP0434249A2 (en) * | 1989-12-01 | 1991-06-26 | Glaxo Group Limited | Benzofuran derivatives |
EP0499414A2 (en) * | 1991-02-11 | 1992-08-19 | Zeneca Limited | Pyridine derivatives as angiotensin II antagonists, processes for their preparation and pharmaceutical compositions containing them |
Non-Patent Citations (12)
Title |
---|
AMBROSIONI, E. ET AL: "EARLY TREATMENT OF ACUTE MYOCARDIAL INFARCTION WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITION: SAFETY CONSIDERATIONS", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 68, no. 14, 1991, pages 101D - 110D, XP008013432 * |
DATABASE WPI Week 8646, Derwent World Patents Index; AN 86-305115, XP003005062 * |
DOSTAL, D.E. ET AL: "EVIDENCE FOR A ROLE OF AN INTRACARDIAC RENIN-ANGIOTENSIN SYSTEM IN NORMAL AND FAILING HEARTS", TRENDS IN CARDIOVASCULAR MEDICINE, vol. 3, no. 2, March 1993 (1993-03-01), pages 67 - 74, XP008013435 * |
FLEETWOOD, G. ET AL: "INVOLVEMENT OF THE RENIN-ANGIOTENSIN SYSTEM IN ISCHEMIC DAMAGE AND REPERFUSION ARRHYTHMIAS IN THE ISOLATED PERFUSED RAT HEART", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 17, no. 3, March 1991 (1991-03-01), pages 351 - 356, XP001034011 * |
GARR, M.D. ET AL: "THE INFLUENCE OF AN ANGIOTENSIN II INHIBITOR (DUP 532) ON VENTRICULAR REMODELLING IN A CANINE MODEL OF DISCRETE MYOCARDIAL DAMAGE", CLINICAL RESEARCH, vol. 40, no. 3, October 1992 (1992-10-01), pages 702A, XP008013434 * |
MOYÉ L.A. ET AL: "RATIONALE, DESIGN AND BASELINE CHARACTERISTICS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 68, 1991, pages 70D - 79D, XP008013431 * |
NABEL, E.G. ET AL: "A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF COMBINED EARLY INTRAVENOUS CAPTOPRIL AND RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR THERAPY IN ACUTE MYOCARDIAL INFARCTION", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 17, no. 2, February 1991 (1991-02-01), pages 467 - 473, XP008010950 * |
PFEFFER, J.M.: "PROGRESSIVE VENTRICULAR DILATATION IN EXPERIMENTAL MYOCARDIAL INFARCTION AND ITS ATTENUATION BY ANGIOTENSIN-CONVERTING ENZYME INHIBITION", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 68, no. 14, 18 November 1991 (1991-11-18), pages 17D - 25D, XP008013430 * |
PFEFFER, M.A. ET AL: "EFFECT OF CAPTOPRIL ON PROGRESSIVE VENTRICULAR DILATATION AFTER ANTERIOR MYOCARDIAL INFARCTION", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 319, no. 2, 14 July 1988 (1988-07-14), pages 80 - 86, XP008013437 * |
SHARPE, N. ET AL: "TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION", THE LANCET, vol. I, no. 8580, 6 February 1988 (1988-02-06), pages 255 - 259, XP001109638 * |
SMITS, J.F. ET AL: "ANGIOTENSIN II RECEPTOR BLOCKADE AFTER MYOCARDIAL INFARCTION IN RATS: EFFECTS ON HEMODYNAMICS, MYOCARDIAL DNA SYNTHESIS, AND INTERSTITIAL COLLAGEN CONTENT", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 20, no. 5, November 1992 (1992-11-01), pages 772 - 778, XP008013433 * |
ST. JOHN SUTTON, M. ET AL: "SURVIVAL AND VENTRICULAR ENLARGEMENT (SAVE) QUANTITATIVE 2D ECHO SUBSTUDY: EFFECTS OF ACE INHIBITION THERAPY ON VENTRICULAR ENLARGEMENT", SUPPLEMENT TO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 19, no. 3, 1 March 1992 (1992-03-01), pages 205A, XP008013425 * |
Also Published As
Publication number | Publication date |
---|---|
AU4281093A (en) | 1993-11-18 |
DE69333362T2 (en) | 2005-01-27 |
EP0641218B2 (en) | 2007-11-14 |
DK0641218T4 (en) | 2008-01-02 |
DK0641218T3 (en) | 2004-03-29 |
ES2211867T5 (en) | 2008-04-01 |
US5972990A (en) | 1999-10-26 |
EP0641218B1 (en) | 2003-12-17 |
EP0641218A1 (en) | 1995-03-08 |
EP1262175A2 (en) | 2002-12-04 |
EP1262175A3 (en) | 2003-04-09 |
WO1993020839A2 (en) | 1993-10-28 |
ES2211867T3 (en) | 2004-07-16 |
DE69333362T3 (en) | 2008-06-12 |
CA2117782A1 (en) | 1993-10-28 |
DE69333362D1 (en) | 2004-01-29 |
US5952305A (en) | 1999-09-14 |
JPH07505884A (en) | 1995-06-29 |
CA2117782C (en) | 2008-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993020839A3 (en) | Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality | |
CA2081564A1 (en) | Synergistic therapeutic compositions and methods | |
EA200100418A1 (en) | COMBINED THERAPY WITH THE USE OF ANGIOTENZIN CONVERSION AND ANTAGONIST ALDOSTERONE ENVIRONMENTAL INHIBITOR TO REDUCE INCIDENCE AND MORTALITY IN CARDIOVASCULAR DISEASES | |
BR9711447A (en) | Use of glp-1 analogs in the treatment of radio myocardial infarction | |
RU92016534A (en) | SYNERGETIC THERAPEUTIC COMPOSITIONS AND METHODS OF ACHIEVING THE SYNERGETIC THERAPEUTIC EFFECT | |
MY133569A (en) | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors | |
EA199900553A1 (en) | Percutaneous therapy system | |
EP1059100A3 (en) | Combinations of CRF antagonists and renin-angiotensin system inhibitors | |
EG18081A (en) | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as the use indurugs | |
EA199900045A1 (en) | DERIVATIVES OF SPIROPIPERIDINE AND THEIR USE AS THERAPEUTIC AGENTS | |
UA41355C2 (en) | Agent for treating neuro-aids | |
IL130083A0 (en) | 3-Pyridyl enantiomers and their use as analgesics | |
MX9706957A (en) | Composition containing amlodipine, or a salt or felodipine and anace inhibitor. | |
CA2291160A1 (en) | Combination therapy for modulating the human sexual response | |
MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
EP0992243A4 (en) | Prophylactic/remedial agent | |
CA2055948A1 (en) | Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria | |
ES2175437T3 (en) | COMPOSITION OF ENALAPRIL AND LOSARTAN. | |
IS4847A (en) | Method for the treatment of heart failure using endothelin antagonists | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
MX9705916A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc. | |
NO993399L (en) | Use of angiotensin II antagonists to treat symptomatic heart failure | |
AU7854094A (en) | Use of amiodarone for the treatment of heart failure | |
NZ515727A (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
AU1067695A (en) | Use of lithium compounds in the treatment of cardiac insufficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2117782 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993912155 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993912155 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993912155 Country of ref document: EP |